TY - JOUR T1 - Asthma medication use during pregnancy, wheeze and estimated exposure to ambient nitrogen dioxide JF - European Respiratory Journal JO - Eur Respir J SP - 538 LP - 540 DO - 10.1183/09031936.00161514 VL - 45 IS - 2 AU - Janneane F. Gent AU - Julie M. Kezik AU - Melissa E. Hill AU - Lisa A. McKay AU - Theodore R. Holford AU - Brian P. Leaderer AU - Michael B. Bracken Y1 - 2015/02/01 UR - http://erj.ersjournals.com/content/45/2/538.abstract N2 - Asthma affects 8–9% of pregnant women in the USA [1]. Since asthma exacerbations during pregnancy can lead to poor pulmonary function, hypoxia and other adverse health outcomes for the mother, fetus and neonate [2, 3], maintaining good control of asthma during pregnancy is recommended for the health of both mother and baby [4]. Reviews of the safety of asthma medication use during pregnancy suggest no or minimal effects on fetal growth and perinatal complications [4–6]. In spite of this, many pregnant women choose to reduce or stop their asthma medications [7].Risk of wheeze associated with ambient NO2 exposure is higher for pregnant asthmatics who have reduced their medication http://ow.ly/EBRFJ ER -